Key Performance
More- Earnings Score: N/A
- Momentum Score: 15
- True Yield: N/A
- Financial Health Score: N/A
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
A securities fraud investigation into PROCEPT BioRobotics Corporation continues following the company's February 25, 2026 earnings report, which disclosed larger-than-expected adjusted EBITDA losses and cut full-year 2026 revenue guidance from $410-$430 million to $390-$410 million. The stock fell $4.21 per share (15.12%) to $23.63 on the news. The law firm is seeking investors who lost money to participate in potential claims.
04/22/2026, 5:00 PM • Benzinga
The Law Offices of Frank R. Cruz is investigating PROCEPT BioRobotics Corporation for possible federal securities law violations. On February 25, 2026, the company reported larger-than-expected adjusted EBITDA losses and cut its 2026 revenue guidance from $410-430 million to $390-410 million, citing reduced U.S. consumable revenue due to elimination of bulk purchase discounts. The stock fell $4.21 per share (15.12%) to $23.63 on the news.
04/22/2026, 2:07 PM • Benzinga
A securities fraud investigation has been launched into PROCEPT BioRobotics (NASDAQ: PRCT) following the company's February 25, 2026 earnings report, which disclosed larger-than-expected adjusted EBITDA losses and a significant downward revision of full-year 2026 revenue guidance from $410-$430 million to $390-$410 million. The announcement triggered a 15.12% stock price decline ($4.21 per share) on February 26, 2026.
03/10/2026, 2:00 PM • Benzinga
The Law Offices of Frank R. Cruz announced an investigation into PROCEPT BioRobotics Corporation for possible violations of federal securities laws. The investigation follows the company's February 25, 2026 earnings report, which disclosed larger-than-expected adjusted EBITDA losses and a significant cut to full-year 2026 revenue guidance from $410-$430 million to $390-$410 million. The stock fell $4.21 per share (15.12%) to $23.63 on February 26, 2026.
03/09/2026, 11:26 PM • Benzinga
The Schall Law Firm is investigating PROCEPT BioRobotics Corporation for potential securities law violations. The company reported Q4 2025 results on February 25, 2026, with quarterly revenue significantly below analyst expectations and substantially reduced full-year guidance. The company attributed underperformance to realignment disruptions and elimination of bulk-purchase discounts, resulting in a 15.1% stock price decline.
03/08/2026, 7:40 PM • Benzinga
Pomerantz LLP is investigating potential securities fraud claims against PROCEPT BioRobotics Corporation after the company reported Q4 2025 revenue that missed analyst expectations and significantly cut its 2026 revenue guidance from $410-$430 million to $390-$410 million, citing commercial organization disruptions and elimination of bulk-purchasing discounts. The stock fell 15.12% on the news.
03/03/2026, 4:39 PM • GlobeNewswire
Procept (PRCT) Q2 Revenue Jumps 48%
Procept BioRobotics reported strong Q2 2025 financial results with 48.3% revenue growth, reaching $79.2 million, driven by increased U.S. and international sales of robotic surgical systems for BPH treatment.
08/06/2025, 8:32 PM • The Motley Fool
PROCEPT BioRobotics announced leadership transition with Dr. Reza Zadno retiring and Larry L. Wood becoming the new president and CEO effective September 2, 2025. The company also pre-announced Q2 2025 revenue of $79.2 million, representing 48% annual growth.
07/24/2025, 6:00 PM • GlobeNewswire
Aquablation® Therapy’s Assigned Category I Code in 2026 Medicare Proposed Physician Fee Schedule
PROCEPT BioRobotics announced a new Category I CPT code for Aquablation therapy, effective January 1, 2026, with Medicare payment rates comparable to traditional TURP procedures, signaling broader recognition and potential adoption of their BPH treatment technology.
07/14/2025, 9:15 PM • GlobeNewswire
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology in the United States and internationally. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally invasive urologic surgery focusing on treating benign prostatic hyperplasia. The company also provides HYDROS Robotic System, which provides Aquablation therapy image-guided robotic therapy to treat males suffering from lower urinary tract symptoms due to benign prostatic hyperplasia. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in San Jose, California.